ROME Therapeutics

ROME Therapeutics is a biotechnology company pioneering a new approach to treating serious diseases like cancer and autoimmune disorders. They focus on the "dark genome," the 98% of the human genome that has traditionally been overlooked, and believe it holds the key to developing breakthrough therapies. Their research centers on repetitive elements within the dark genome, particularly LINE-1, a virus-like element that can trigger inflammation and contribute to diseases when activated.

ROME has developed a data science platform and a pipeline of therapies targeting the dark genome. Their lead program is a first-in-class inhibitor of LINE-1 reverse transcriptase, which is currently in preclinical development for autoimmune diseases. They have assembled a world-class team of experts in immunology, oncology, chemistry, and machine learning to lead this exploration and are backed by a group of prominent investors.

ROME Therapeutics offers a flexible work approach and flexible Paid Time Off, allowing employees to manage their work-life balance. They also provide 12 weeks of parental leave and employer HSA contributions, demonstrating their commitment to employee well-being and creating a supportive work environment.

ROME Therapeutics prioritizes its employees' well-being and offers a comprehensive benefits package that includes comprehensive health insurance, a flexible work approach, flexible paid time off, 12 weeks of parental leave, employer HSA contributions, an employee assistance program, fitness reimbursement, and community involvement opportunities. In addition to these benefits, employees also receive competitive salaries, annual bonuses, equity, transportation, parking, and cell phone subsidies, life and disability insurance, and a 401(k) with company match.

ROME Therapeutics is a biotechnology company dedicated to developing novel therapies for serious diseases, including autoimmune disease, cancer, and neurodegeneration, by harnessing the potential of the "dark genome." They believe the dark genome holds the key to developing breakthrough treatments and are committed to unlocking its secrets to improve the lives of patients. Their unique approach focuses on targeting disease-relevant consequences of repeat dysregulation, utilizing a proprietary data science platform to identify and advance new therapies.

ROME Therapeutics fosters a culture that values collaboration, curiosity, boldness, and a deep passion for improving patients' lives. They embrace a spirit of exploration and innovation, encouraging their team to fearlessly push boundaries in the field of dark genome research. The company prioritizes a supportive and inclusive environment where employees feel valued and empowered to contribute their unique talents and perspectives.

ROME Therapeutics is committed to fostering a culture that embraces diversity, equity, and inclusion. They believe that a diverse and inclusive team leads to better science and innovation. This commitment is reflected in their hiring practices, employee development programs, and company culture. They actively seek out and support diverse talent and create an environment where everyone feels valued, respected, and empowered to contribute their unique perspectives.